Prostate cancer recurrent

7 trials 5 recruiting MedDRA PT
7 Registered trials
5 Recruiting
6 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Radiopharmaceutical 1 substance
Phase III: 2 Phase I: 3 Phase I (First in Human): 2

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Janssen - Cilag International Commercial
    APALUTAMIDE
    2023-505852-23-00 13 countries 2020 n=290
    Ended
  • Karolinska University Hospital Academic
    (3S,10S,14S)-1-[4-[[(2S)-4-CARBOXY-2-[(2S)-4-CARBOXY-2-(6-[18F] FLUOROPYRIDIN-3-AMIDO)BUTANAMIDO]BUTANAMIDO]METHYL]PHENYL]-3-[(NAPHTHALEN-2-YL)METHYL]-1,4,12-TRIOXO-2,5,11,13-TETRAAZAHEXADECANE-10,14,16-TRICARBOXYLIC ACID; GOZETOTIDE
    2023-504917-54-00 1 country 2018 n=450
    Recruiting

Phase I

3 trials
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2025-521886-28-00 1 country 2026 n=15
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2023-504063-17-00 2 countries 2024 n=71
    Recruiting
  • Universitaetsklinikum Tuebingen AöR Academic
    IMP not specified
    2024-511430-12-00 1 country 2022 n=56
    Recruiting

Phase I (First in Human)

2 trials
  • SpectraCure AB (publ) Commercial
    IMP not specified
    2022-502285-24-00 2 countries 2024 n=26
    Recruiting
  • Amsterdam UMC Stichting Academic
    LUTETIUM (177LU) ZADAVOTIDE GURAXETAN; RADIUM RA 223 DICHLORIDE
    2024-518985-29-02 1 country 2024 n=6
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 2 Phase I, Phase III 1
Daiichi Sankyo Inc. Commercial 1 Phase I 1
SpectraCure AB (publ) Commercial 1 Phase I (First in Human) 1
Universitaetsklinikum Tuebingen AöR Academic 1 Phase I 1
Karolinska University Hospital Academic 1 Phase III 1
Amsterdam UMC Stichting Academic 1 Phase I (First in Human) 0
New trials by year
2020
1
2022
1
2024
3
2026
1
← All indication landscapes